Navigation Links
Usability Sciences Corporation Launches WebIQ Pharma - An Intelligent Survey Tool That Allows Pharma Sites to Measure and Improve Website Effectiveness

IRVING, Texas, March 23 /PRNewswire/ -- Usability Sciences Corporation launches its WebIQ Pharma offering, an intelligent survey solution that provides pharmaceutical sites with metrics to answer critical questions about site and content effectiveness, to increase return on investment (ROI).  Usability Sciences has provided usability and user experience research to Merck (MRK), Eli Lilly (LLY), Novartis (NVS) and Ortho McNeil for over ten years.

Pharmaceutical brands build websites primarily to drive drug adoption. The brands want site visitors who have never tried the drug to make appointments with their doctors to discuss the drug. The brands want visitors who have been prescribed the drug to keep taking it and get their prescriptions refilled. Most importantly, the brands need to know which content areas drive the desired behaviors and which content areas do not.  Establishing the link between visitor response to the site and the content that determined their response has heretofore been extremely difficult. WebIQ Pharma makes it simple and, compared to the labor-intensive alternatives, extremely cost effective.

"WebIQ Pharma employs intelligent survey technology and intelligent dashboards in delivering this patented solution," said Usability Sciences President Jeff Schueler. "The intelligent survey technology allows the brand to ask questions of site visitors based on where they went on the site and what content they saw. WebIQ Pharma dashboards, rather than deliver more 'dumb' data, provide answers to the site's key business questions."

Usability Sciences developed the methodology specifically for the pharmaceutical industry, where brand sites often carry high costs but generate relatively low traffic. WebIQ Pharma arms the brand with a continuous stream of answers to drug adoption questions and allows them to constantly improve site stickiness, conversion, and ROI. WebIQ Pharma is flexible and can be customized to fit any brand's needs and preferences in terms of options and pricing.

More information can be found at or by contacting the company directly at

About Usability Sciences:

With more than 20 years of experience in the usability and user experience arena, Usability Sciences has developed an industry-leading portfolio of research methodologies that delivers robust and actionable results to its Fortune 500 client base. For more information about Usability Sciences' service offerings, go to or call 1-800-820-1222.

    Press Release Contact Information:
    Jeff Schueler
    Media Liaison
    Usability Sciences Corporation
    (972) 550-1599

This release was issued through WebWire(R). For more information visit

SOURCE Usability Sciences Corporation

Back to top



SOURCE Usability Sciences Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alegent Health Sees Positive Results From Recent Clinician Usability Study Collaboration With Siemens and Motion Computing
2. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
3. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
4. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
5. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
6. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
7. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
8. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
9. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
10. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Alfacell Corporation to Present at UBS Global Life Sciences Conference
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 3D ... by 2022, according to a new report by Grand View ... Kidney Disease (CKD) which demands kidney transplantation is expected to ... cost effective substitute for organ transplantation. --> 3D ... by 2022, according to a new report by Grand View ...
(Date:11/26/2015)... November 26, 2015 ... the "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Country Segment Forecasts, ... their offering. --> ) ... "2016 Future Horizons and Growth Strategies in ...
(Date:11/26/2015)... November 26, 2015 ... adds "Global Repaglinide Industry ... Report on China Repaglinide Market, 2010-2019" ... data and information to its online ... . --> ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... 2015 , ... Beddit® has launched a new Android app for ... features a more intuitive SleepScore™ that rates sleep quality on a 100-point scale and ... created by a proprietary algorithm. Beddit analyzes the data to provide an easy to ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... In an ... Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of ... and surgical intensive care units (totaling 30 beds) from May 2014 through October 2015 ...
(Date:11/25/2015)... ... ... Today, Mothers Against Drunk Driving (MADD) learned that the number of ... time since 2011. In 2014, there were 9,967 fatalities involving an alcohol impaired driver, ... Traffic Safety Administration (NHTSA), 32,675 people were killed in traffic crashes in 2014. Drunk ...
(Date:11/25/2015)... Silver Spring, Md (PRWEB) , ... November 25, ... ... the Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups ... the history of this disease. The Periwinkle Pioneers, nominated by the public, will ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... announced that it has undertaken significant expansion of its current state of the ... is part of PharmaTech’s strategy to increase its manufacturing capacity as well as ...
Breaking Medicine News(10 mins):